FDA pushes back release of pharmacogenomics guidance

Share this article:
The FDA has delayed the release of its Guidance for Industry on Pharmacogenomic Data Submissions from today to March 22, according to a Web site report from Genome Web News.
The long-awaited guidance is expected to provide a map for drug developers to step up the science of tailoring drugs to people and ultimately improve drug safety, efficacy and help avoid Vioxx-like withdrawals. Pharmacogenomics uses a DNA test to help doctors decide if a medicine is suitable for a patient.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions